Class information for:
Level 1: PCSK9//PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9//MIPOMERSEN

Basic class information
ID Publications Average number
of references		 Avg. shr. active
ref. in WoS
14996 668 43.5 90%


Bar chart of Publication_year

Last years might be incomplete

Classes in level above (level 2)


ID, lev.
above		 Publications Label for level above
56 28576 CHOLESTERYL ESTER TRANSFER PROTEIN//JOURNAL OF LIPID RESEARCH//HIGH DENSITY LIPOPROTEIN

Terms with highest relevance score


Rank Term Type of term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 PCSK9 Author keyword 231 73% 26% 175
2 PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 Author keyword 105 83% 9% 59
3 MIPOMERSEN Author keyword 33 64% 5% 32
4 ALIROCUMAB Author keyword 29 88% 2% 14
5 PROPROTEIN CONVERTASE SUBTILISIN KEXIN 9 Author keyword 20 100% 1% 9
6 PCSK9 INHIBITORS Author keyword 19 76% 2% 13
7 EVOLOCUMAB Author keyword 15 82% 1% 9
8 PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 PCSK9 Author keyword 11 69% 1% 9
9 BIOCHEM NEUROENDOCRINOL Address 10 19% 7% 46
10 NARC 1 Author keyword 9 83% 1% 5

Web of Science journal categories

Author Key Words


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class		 LCSH search Wikipedia search
1 PCSK9 231 73% 26% 175 Search PCSK9 Search PCSK9
2 PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 105 83% 9% 59 Search PROPROTEIN+CONVERTASE+SUBTILISIN+KEXIN+TYPE+9 Search PROPROTEIN+CONVERTASE+SUBTILISIN+KEXIN+TYPE+9
3 MIPOMERSEN 33 64% 5% 32 Search MIPOMERSEN Search MIPOMERSEN
4 ALIROCUMAB 29 88% 2% 14 Search ALIROCUMAB Search ALIROCUMAB
5 PROPROTEIN CONVERTASE SUBTILISIN KEXIN 9 20 100% 1% 9 Search PROPROTEIN+CONVERTASE+SUBTILISIN+KEXIN+9 Search PROPROTEIN+CONVERTASE+SUBTILISIN+KEXIN+9
6 PCSK9 INHIBITORS 19 76% 2% 13 Search PCSK9+INHIBITORS Search PCSK9+INHIBITORS
7 EVOLOCUMAB 15 82% 1% 9 Search EVOLOCUMAB Search EVOLOCUMAB
8 PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 PCSK9 11 69% 1% 9 Search PROPROTEIN+CONVERTASE+SUBTILISIN+KEXIN+TYPE+9+PCSK9 Search PROPROTEIN+CONVERTASE+SUBTILISIN+KEXIN+TYPE+9+PCSK9
9 NARC 1 9 83% 1% 5 Search NARC+1 Search NARC+1
10 AMG 145 6 100% 1% 4 Search AMG+145 Search AMG+145

Key Words Plus


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 SUBTILISIN KEXIN TYPE 9 197 77% 20% 133
2 AUTOSOMAL DOMINANT HYPERCHOLESTEROLEMIA 187 66% 26% 173
3 SECRETED PCSK9 166 90% 11% 72
4 PLASMA PCSK9 80 90% 5% 35
5 CONVERTASE SUBTILISIN KEXIN TYPE 9 76 93% 4% 28
6 PROPROTEIN CONVERTASE PCSK9 56 100% 3% 19
7 AMG 145 46 76% 5% 32
8 PCSK9 43 41% 12% 80
9 PLASMA PCSK9 LEVELS 34 93% 2% 13
10 B SYNTHESIS INHIBITOR 34 70% 4% 28

Journals

Reviews


Title Publ. year Cit. Active references % act. ref.
to same field
PCSK9: A Key Modulator of Cardiovascular Health 2014 30 131 79%
PCSK9 inhibition in LDL cholesterol reduction: Genetics and therapeutic implications of very low plasma lipoprotein levels 2015 5 96 71%
Clinical aspects of PCSK9 2011 50 82 93%
Lipid lowering with PCSK9 inhibitors 2014 25 86 69%
The PCSK9 decade 2012 81 96 95%
Proprotein convertase subtilisin/kexin type 9 (PCSK9): From structure-function relation to therapeutic inhibition 2011 36 72 94%
PCSK9: From discovery to therapeutic applications 2014 12 46 91%
Clinical pharmacological properties of mipomersen (Kynamro), a second generation antisense inhibitor of apolipoprotein B 2013 22 16 81%
Targeting PCSK9 for Hypercholesterolemia 2014 10 103 95%
Reduction of Low-Density Lipoprotein Cholesterol by Monoclonal Antibody Inhibition of PCSK9 2014 14 29 76%

Address terms


Rank Address term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 BIOCHEM NEUROENDOCRINOL 10 19% 6.9% 46
2 UNIT CARDIAC CARDIOVASC GENET 6 53% 1.2% 8
3 ENDOCRINOL DIABET PREVENT MED ZEDP 4 75% 0.4% 3
4 FUNCT ENDOPROTEOLYSIS 4 75% 0.4% 3
5 CARBOHYDRATE LIPID METAB UNIT 4 28% 1.6% 11
6 ENDOCRINOL METABCLIN 3 100% 0.4% 3
7 DYSLIPIDEMIASTATE CARDIOVASC DIS 3 33% 1.0% 7
8 CLIN ENDOCRINOL NUTR 3 50% 0.6% 4
9 SOC ITALIANA STUDIO ATEROSCLEROSI 3 35% 0.9% 6
10 CARDIOVASC DIS DYSLIPIDEMIASTATE KE 2 67% 0.3% 2

Related classes at same level (level 1)


Rank Relatedness score Related classes
1 0.0000269986 FAMILIAL HYPERCHOLESTEROLEMIA//FAMILIAL HYPERCHOLESTEROLAEMIA//LDL RECEPTOR GENE
2 0.0000092076 EZETIMIBE//CHOLESTEROL ABSORPTION INHIBITOR//COLESEVELAM
3 0.0000085555 MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN//HYPOBETALIPOPROTEINEMIA//APOLIPOPROTEIN B
4 0.0000084048 TORCETRAPIB//HIGH DENSITY LIPOPROTEIN//ANACETRAPIB
5 0.0000076931 CHROMOSOME 9P21//PSMA6//9P21
6 0.0000076593 LIPOPROT UNIT//LIPOPROTEIN KINETICS//OURCE IL KINET ANAL
7 0.0000071226 SREBP//SCAP//INSIG
8 0.0000057222 STATINS//LOW DENSITY LIPOPROTEIN CHOLESTEROL//ATORVASTATIN
9 0.0000054593 LDL APHERESIS//LOW DENSITY LIPOPROTEIN APHERESIS//LIPOPROTEIN APHERESIS
10 0.0000054514 NK 104//PITAVASTATIN//CAS 147526 32 7